Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
Crispr Therapeutics Ag revenue decreases to $100 million in quarter ended Mar 31, 2023 from previous quarter
By USInMinutes - May 08, 2023, 10:22 PM ET
Last Updated - Jul 18, 2023, 03:33 PM EDT
Key fundamental financials- loss of $53.06 million
- Revenue of $100 million
| Current Reporting | Revenue | Net Income | Profit/Loss |
|---|---|---|---|
| Mar 2023 | $100 million | $53.06 million | loss |
| Sep 2022 | $94 | $174,549 | loss |
| Jun 2022 | $158,000 | $185.83 million | loss |
Crispr Therapeutics Ag [CRSP] has reported $53.06 million loss for the fiscal quarter ending Mar 31, 2023.
Revenue for the quarter was $100 million with operating income of $64.49 million.
Also read:
This is a developing story. Click here to receive updates.
------------
NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.
Sponsored
Read More from Quarterly Reports
Read More from USinMinutes
Popular News
Latest News
